

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED**

**精優藥業控股有限公司\***

*(incorporated in Bermuda with limited liability)*

**(Stock Code: 00858)**

### **Clarification Announcement in relation to the Chinese version of the Positive Profit Alert Announcement**

Reference is made to the announcement of Extrawell Pharmaceutical Holdings Limited (the “**Company**”) dated 11 November 2014. The board of directors (“**Board**”) of the Company has noted typographical errors in the second paragraph of the Chinese version of the announcement and wishes to make the corrections as underlined:

“本公司董事會(「**董事會**」)謹此知會本公司之股東(「**股東**」)及潛在投資者，根據就本集團截至二零一四年九月三十日止六個月期間之未經審核綜合管理賬目(「**管理賬目**」)之初步評估，本集團預期期內的溢利與截至二零一三年九月三十日止期間的溢利相比，將錄得大幅增加。……”

By order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Xie Yi**  
*Chairman*

Hong Kong, 12 November 2014

*As at the date of this announcement, the executive directors are Dr. Xie Yi, Dr. Lou Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen and Mr. Liu Kwok Wah and the independent non-executive directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.*

\* *For identification purpose only*